Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duvoglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 1.00 |
| ▸ | GLA known ✓ | P06280 | 4/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 1.00 |
| ▸ | MGAM | O43451 | 4/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | LCT | P09848 | 2/20 | 1.00 |
| ▸ | GBA3 | Q9H227 | 2/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 1.00 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TREH | O43280 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duvoglustat SCHEMBL13298786 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL15896653 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL142573 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL10028910 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12269503 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL24518227 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL2163281 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL13061461 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL21104989 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL9015606 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348388-A1 | Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same | AMICUS THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348388-A1 | Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same | AMICUS THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-11685718-B2 | Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds | AMICUS THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685718-B2 | Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds | AMICUS THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4076533-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2022-10-26 | — | — | EP | disclosed |
| US-20220194899-A1 | HIGHLY PURIFIED BATCHES OF PHARMACEUTICAL GRADE 1-DEOXYGALACTONOJIRIMYCIN COMPOUNDS | AMICUS THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220185776-A1 | Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same | AMICUS THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| EP-1554245-B1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDSYNTHASE | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-26 | — | — | EP | disclosed |
| EP-1641755-B1 | 2-HYDROXYMETHYL-3,4,5-TRIHYDROXY-1-(4-PENTLYOXYBENZYL)PIPERIDINE AS GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITOR | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-8022219-B2 | 2-hydroxymethy1-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine as glucosylceramide synthase (Gcs) inhibitor | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-20 | — | — | US | disclosed |
| US-8022219-B2 | 2-hydroxymethy1-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine as glucosylceramide synthase (Gcs) inhibitor | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-20 | — | — | US | disclosed |
| US-7994198-B2 | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994198-B2 | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-1888612-A1 | CRYSTALLINE SUGAR COMPOSITIONS AND METHOD OF MAKING | Amicus Therapeutics, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070259918-A1 | 2-Hydroxymethyl-3,4,5-Trihydroxy-1-(4-Pentyloxybenzyl) Piperidine as Glucosylceramide Synthase (Gcs) Inhibitor | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-11-08 | — | — | US | disclosed |
| US-20070259918-A1 | 2-Hydroxymethyl-3,4,5-Trihydroxy-1-(4-Pentyloxybenzyl) Piperidine as Glucosylceramide Synthase (Gcs) Inhibitor | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-11-08 | — | — | US | disclosed |
| US-20060293250-A1 | Crystalline sugar compositions and method of making | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-12-28 | — | — | US | disclosed |
| WO-2006133447-A1 | CRYSTALLINE SUGAR COMPOSITIONS AND METHOD OF MAKING | AMICUS THERAPEUTICS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185776-A1 | Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same | UGT8, GALC, GANAB | GAA 17/4885GLA 9/4885FUCA1 252/4885 |
| US-20060293250-A1 | Crystalline sugar compositions and method of making | MGAM, DAD1, UGDH | GAA 126/4885GLA 172/4885FUCA1 101/4885 |
| US-20230348388-A1 | Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same | GANAB, GALK1, GANC | GAA 6/4885GLA 5/4885FUCA1 1919/4885 |
| US-11685718-B2 | Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds | GALK1, GANAB, MGAM | GAA 12/4885GLA 6/4885FUCA1 1336/4885 |
| US-20070259918-A1 | 2-Hydroxymethyl-3,4,5-Trihydroxy-1-(4-Pentyloxybenzyl) Piperidine as Glucosylceramide Synthase (Gcs) Inhibitor | UGCG, CERS2, GBA1 | GAA 63/4885GLA 136/4885FUCA1 489/4885 |
| US-20220194899-A1 | HIGHLY PURIFIED BATCHES OF PHARMACEUTICAL GRADE 1-DEOXYGALACTONOJIRIMYCIN COMPOUNDS | GALK1, GANAB, MGAM | GAA 12/4885GLA 6/4885FUCA1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.